Bone marrow dosimetry in rats using direct tissue counting after injection of radio-iodinated intact monoclonal antibodies or F(ab')2 fragments.

Normal rats were injected intravenously with 131I- and 125I-labeled intact murine and chimeric mouse-human monoclonal antibodies directed against carcinoembryonic antigen or with the corresponding F(ab')2 fragments. At different times after injection, individual animals were killed and radioactivity of blood and major organs, including bones and bone marrow, was determined. Ratios comparing radioactivity concentration in different tissues with that of bone marrow were calculated and found to remain stable during several effective half-lives of the antibodies. Mean bone marrow radioactivity was 35% (range, 29%-40%) of that of blood and 126% (range, 108%-147%) of that of liver after injection of intact Mabs or F(ab')2 fragments. In nude rats bearing human colon carcinoma xenografts producing carcinoembryonic antigen, relative bone marrow radioactivity was slightly lower than that in normal rats.

Ex XIIII. T. Livii Decadibus. Prima, tertia, quarta, in qua praeter fragmenta III, & X libri, quae in Germania nuper reperta, hic etiam continentur, multa adulterina expunximus, multa vera recepimus, quae in aliis non habentur. Epitome singulorum librorum XIIII Decadum. Historia omnium XIIII Decadum in compendium redacta ab L. Floro. Polybii lib. V de rebus Romanis latinitate donati à Nicolao Perotto. Index copiosissimus rerum omnium memorabilium...

[Histoire romaine (latin). 1518-1533]

Ex XIIII. T. Livii Decadibus. Prima, tertia, quarta, in qua praeter fragmenta III, & X libri, quae in Germania nuper reperta, hic etiam continentur, multa adulterina expunximus, multa vera recepimus, quae in aliis non habentur. Epitome singulorum librorum XIIII Decadum. Historia omnium XIIII Decadum in compendium redacta ab L. Floro. Polybii lib. V de rebus Romanis latinitate donati à Nicolao Perotto. Index copiosissimus rerum omnium memorabilium...

[Histoire romaine (latin). 1518-1533]

Reliure de : Blondi Flavii Forliviensis historiarum ab inclinatione Romanorum libri XXXI... - "A la fin" : Basileae, in officina Frobeniana per Hieronymum Frobenium, Ioannem Hervagium et Nicolaum Episcopium. Anno MDXXXI mense Martio

Numérisation partielle de reliure

Reliure de : De Romanorum militia et castrorum metatione liber... ex Polybii historiis per A. Janum Lascarem,... excerptus, et ab eodem latinitate donatus, ipso etiam graeco libro, ut omnia conferri possint... adjuncto. Ejusdem A. Jani Lascaris Epigrammata et graeca et latina... Item Jacobi, comitis Purliliarum de re militari lib. II. Ad aetatis nostrae bellandi rationem... necessarii. [Edidit Jo Oporinus.]

Numérisation partielle de reliure

M. Tullii Ciceronis opera, omnium quae hactenus excusa sunt castigatissima, nunc primum in lucem edita (a Petro Victorio). Secundus tomus M. T. Ciceronis orationes habet, ab Andrea Naugerio, in suam integritatem restitutas

Comprend : Explicationes suarum in Ciceronem castigationum

Clinical value of immunoscintigraphy in colorectal carcinoma patients: a prospective study.

Fifty-seven patients with suspected CEA-producing tumors were studied prospectively by radioimmunoscintigraphy (RIS) using a 123I-labeled anti-CEA monoclonal antibody (MAb) (essentially the F(ab')2 or Fab fragments) and emission computed tomography (ECT). Results of RIS were compared to those of a comprehensive diagnostic study. Final diagnosis was based on surgery, biopsy and autopsy (n = 39) or follow-up findings (n = 18). Three groups of patients were defined: Group A with suspected primary tumors (n = 11), Group B with probable (n = 19) and Group C with questionable (n = 27) tumor relapse. Eighty-eight per cent, 93% and 71% of the anatomic regions studied were correctly identified as being involved, and 97%, 97%, and 87% as being free from tumor in Groups A, B, and C, respectively. In the 27 patients from Group C with no definite diagnosis of relapse, and in whom diagnosis was most difficult, 38 tumor sites were involved. Of these, 21 were detected by both prospective RIS and repeated comprehensive study, six by RIS only and seven by conventional methods only. Four sites remained undetected by both approaches. Ten of the 21 lesions were detected by RIS more than 1 mo earlier than by any other method. Among the seven tumor sites detected by other diagnostic modalities only, three were identified at the time of RIS and four became positive more than 6 mo later. Overall diagnosis was entirely correct in 30, partially correct in 16 and incorrect in six patients studied. RIS with ECT and 123I-labeled anti-CEA MAb allows early detection of recurrence or metastasis of colorectal cancer. It thus contributes to reduced delay between diagnosis and treatment.

Restoration of anti-tetanus toxoid responses in patients initiating highly active antiretroviral therapy with or without a boost immunization: an INITIO substudy.

INITIO is an open-labelled randomized trial evaluating first-line therapeutic strategies for human immunodeficiency virus-1 (HIV-1) infection. In an immunology substudy a tetanus toxoid booster (TTB) immunization was planned for 24 weeks after initiation of highly active antiretroviral therapy (HAART). All patients had received tetanus toxoid immunization in childhood. Generation of proliferative responses to tetanus toxoid was compared in two groups of patients, those receiving a protease inhibitor (PI)-sparing regimen (n = 21) and those receiving a PI-containing (n = 54) regimen. Fifty-two participants received a TTB immunization [PI-sparing (n = 15), PI-containing (n = 37)] and 23 participants did not [PI-sparing (n = 6) or PI-containing (n = 17)]. Cellular responses to tetanus antigen were monitored by lymphoproliferation at time of immunization and every 24 weeks to week 156. Proportions with a positive response (defined as stimulation index > or = 3 and Delta counts per minute > or = 3000) were compared at weeks 96 and 156. All analyses were intent-to-treat. Fifty-two participants had a TTB immunization at median 25 weeks; 23 patients did not. At weeks 96 and 156 there was no evidence of a difference in tetanus-specific responses, between those with or without TTB immunization (P = 0.2, P = 0.4). There was no difference in the proportion with response between those with PI-sparing or PI-containing regimens at both time-points (P = 0.8, P = 0.7). The proliferative response to tetanus toxoid was unaffected by initial HAART regimen. Anti-tetanus responses appear to reconstitute eventually in most patients over 156 weeks when treated successfully with HAART, irrespective of whether or not a TTB immunization has been administered.